Company Profile
Trevena Stock Price, News & Catalysts
- Ticker:
- TRVN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.00 USD (0.00%)
Close
Last updated: August 17, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for TRVN.
Company overview
Business overview
Trevena was a specialty neuroscience and pain company focused on opioid-sparing and CNS therapeutics. Its story centered on difficult pain and neurologic indications where commercial uptake depends on both clinical differentiation and regulatory execution.
Geographic Base and Sector Classification
Trevena was headquartered in the United States and listed on NASDAQ, placing it in the small-cap biopharmaceutical category. It sat in the high-risk neuroscience and pain niche rather than broad healthcare.
Business Model Characteristics
The business model was driven by late-stage development, product commercialization attempts, and the ability to secure reimbursement and physician adoption. Investors watched clinical data, product launches, and the company's capital structure closely.
Position Within the Biotechnology Landscape
Trevena occupied a catalyst-sensitive small-cap CNS niche. It is best viewed as a legacy specialty-pharma story where execution risk and funding pressure were always central to the stock.
Future catalysts
- Trevena is now mostly a legacy / closeout story, so the catalysts are any remaining asset or strategic update rather than a fresh development milestone. The market no longer treats it as a live growth name.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Trevena (TRVN)?
Trevena (TRVN) most recently closed at 0.00 USD, a 0.00% move versus the previous session.
What does Trevena do?
Trevena was a specialty neuroscience and pain company focused on opioid-sparing and CNS therapeutics. Its story centered on difficult pain and neurologic indications where commercial uptake depends on both clinical differentiation and regulatory execution.
On which exchange is TRVN stock listed?
Trevena (TRVN) is associated with NASDAQ, United States, Biopharma.
What is Trevena?
Trevena is now mostly a legacy / closeout story, so the catalysts are any remaining asset or strategic update rather than a fresh development milestone.
Which conditions is Trevena targeting with Trevena?
Trevena is associated with neuroscience based on its company overview and current catalyst commentary.
How does Trevena describe recent progress with Trevena?
Trevena is now mostly a legacy / closeout story, so the catalysts are any remaining asset or strategic update rather than a fresh development milestone.
What future catalysts are investors watching for Trevena?
Trevena is now mostly a legacy / closeout story, so the catalysts are any remaining asset or strategic update rather than a fresh development milestone. The market no longer treats it as a live growth name.